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Purpose: To examine the association between selective serotonin reuptake inhibitor (SSRI) 
use and mortality, postoperative complications, and quality of in-hospital care in hip fracture 
patients.
Patients and methods: The study was a nationwide cohort study based on individual-level 
linked, prospectively collected data from Danish population-based national registries covering 
all hospitals in Denmark. The health care system in Denmark is tax-funded, and all citizens have 
equal access to health care services. We included patients with first-time hospitalization due to 
hip fracture undergoing surgery from 2006–2016. We estimated the risk of 30-day mortality, 
any unplanned readmission, any reoperation, specific postoperative complications including 
cardiovascular events and major bleeding, and quality of in-hospital care using Cox and Poisson 
regression analyses comparing current and former SSRI users with non-users.
Results: In 68,487 hip fracture patients, 13,272 (19%) were current SSRI users, 2,777 (4%) 
were former SSRI users, and 52,438 (77%) were SSRI non-users. The 30-day mortality risk 
was 13% in current SSRI users (HR 1.16, 1.10–1.21) and 12% in former (HR 1.15, 1.04–1.27) 
compared with 10% in non-users. The HR for any unplanned readmission was 1.11 (1.02–1.20) 
in current and 1.13 (1.01–1.27) in former SSRI users and for any reoperation 1.21 (1.11–1.31) 
in current and 1.04 (0.84–1.28) in former SSRI users compared with non-users. The risk of 
venous thromboembolism, myocardial infarction, stroke, and bleeding were similar irrespective 
of SSRI use. No association between current and former SSRI use and quality of in-hospital 
care was found.
Conclusion: In patients undergoing hip fracture surgery, 30-day mortality and overall readmis-
sion risk were elevated in both current and former SSRI users compared with non-users. Those 
currently using SSRI had a 26% increased reoperation risk compared with non-users. However, 
SSRI use was not associated with increased risk of other postoperative complications and lower 
quality of in-hospital care. A limitation of this study was the inability to control for potential 
confounding of social deprivation.
Keywords: cohort studies, hip fracture, mortality, postoperative complications, quality of care, 
selective serotonin reuptake inhibitors
Introduction
Hip fracture is a frequent surgical procedure among the elderly.1 It correlates with 
high medical costs and health care utilization2 and confers increased risk of mortal-
ity.3 Thirty-day mortality in elderly surgically treated hip fracture patients is 10% and 
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increases to 30% within 1 year.4 Patients who receive the 
recommended pre- and postoperative in-hospital care such 
as pain assessment, nutritional risk assessment, osteoporosis 
prophylaxis, and basic mobility assessment at admission and 
discharge may have a lower mortality risk compared with 
those who do not.5 Additionally, high mortality is linked to 
the occurrence of postoperative complications, which affect 
~20% of elderly hip fracture patients.5,6 The most common 
postoperative complication is infection.4 However, patients 
can experience venous thromboembolism (VTE), myocar-
dial infarction (MI), stroke, and gastrointestinal bleeding 
as well.4,7
Elderly hip fracture patients are often multimorbid 
and receive multiple prescription medications including 
selective serotonin reuptake inhibitors (SSRIs).8 SSRIs 
are prescribed to 10% of Danish elderly aged 65 years or 
older.9 The most common indications for SSRI prescribing 
are depression and anxiety.10 In general, SSRI use appears 
to increase the risk of mortality, new cardiovascular events, 
and postoperative bleeding.6,11 Previous studies among 
patients undergoing major surgery, including orthopedic 
surgeries, reported higher risk of mortality, readmission, and 
blood transfusion in those using SSRIs perioperatively.12,13 
However, a study including orthopedic patients showed 
no evidence that SSRI use increased the risk of receiving 
a blood transfusion.14 Thus, existing literature examining 
the effect of SSRI use on surgery outcome is somewhat 
inconclusive. The impact of preadmission SSRI use on 
mortality, postoperative complications, and quality of in-
hospital care among elderly and fragile hip fracture patients 
has not been reported previously. Therefore, we conducted 
a nationwide, prospective cohort study examining whether 
preadmission SSRI use is associated with adverse outcomes 
in hip fracture surgery patients.
Ethics approval
Ethical approval was not required according to the Danish 
Act on Research Ethics Review of Health Research Projects 
due to the register-based nature of the study. The study was 
approved by the Danish Data Protection Agency (record 
number: 1-16-02-467-15).
Patients and methods
setting and design
The study is a nationwide cohort study using prospectively 
collected data from Danish medical registries covering all 
Danish citizens; approximately 5.7 million people.15 The 
health care system in Denmark is tax-funded, and all citizens 
have equal access to health care services.
Data sources
The Danish Multidisciplinary Hip Fracture Registry16 has 
routinely registered comprehensive clinical data on all 
patients aged 65 years or older with first-time hip fracture 
admitted to any orthopedic department in Denmark since 
2004. Data include detailed pre- and postoperative data, as 
well as data on quality of in-hospital care represented by 
process-performance measures. The Danish Civil Registra-
tion System17 established in 1968 holds data on date of birth, 
vital status, and migration on all individuals in Denmark. 
Every citizen has a unique civil personal registration number, 
which allows for individual-level linkage across all Danish 
registries. The Danish National Patient Registry18 contains 
data on civil personal registration number, hospital admission 
and discharge diagnosis codes, and diagnostic and surgical 
procedure codes from all Danish somatic hospitals since 
1977. Diagnoses were coded using the ICD-8 until the end of 
1993 and ICD-10 thereafter. The Danish National Database 
of Reimbursed Prescriptions19 tracks reimbursed medicine 
dispensing at all community pharmacies and hospital-based 
outpatient pharmacies in Denmark since 2004. The database 
holds data on civil personal registration number, Anatomical 
Therapeutic Chemical code, redemption date, item quantity, 
pack size, defined daily dose, dose form, and generic substi-
tution done at pharmacy.
Participants
 Patients aged 65 years or older undergoing surgical treatment 
for hip fracture between 2004 and 2016 were identified in the 
Danish Multidisciplinary Hip Fracture Registry. The study 
period was subsequently restricted to patients registered 
between January 1, 2006, and December 31, 2016, to ensure 
at least 2 years prescription history. Patients with missing data 
on operation delay (n=119) were excluded. In total, 68,487 
first-time hip fracture patients who received surgery from 
2006–2016 were available for analyses.
Variables
Exposure
All redeemed prescriptions for SSRIs 1 year before hip 
fracture surgery were identified in the Danish National 
Database of Reimbursed Prescriptions. Patients were classi-
fied according to SSRI use. Current SSRI users redeemed at 
least one prescription within 90 days, former users redeemed 
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one prescription between 91 and 365 days, and non-users 
redeemed no prescriptions within 365 days before hip frac-
ture surgery.
Outcomes
Several outcomes occurring after hip fracture surgery were 
examined separately. First, all-cause 30-day mortality was 
ascertained from the Civil Registration System. Second, 
postoperative complications were ascertained from the Dan-
ish National Patient Registry. The following postoperative 
complications were examined: 1) any unplanned readmission, 
2) any reoperation, 3) cardiovascular events including VTE, 
MI, and stroke, and 4) major bleeding defined as intracranial 
bleeding, gastrointestinal bleeding, or urinary/lung bleeding 
within 30 days of surgery. Third, quality of in-hospital care 
represented by process-performance measures20 including 
preoperative optimization, operation delay, mobilization 
within 24 hours postoperatively, basic mobility assessment at 
admission and discharge, nutritional risk assessment, osteo-
porosis prophylaxis, and future fall prophylaxis were obtained 
from the Danish Multidisciplinary Hip Fracture Registry.
Covariates
Operation year, housing, BMI, fracture type, operation type, 
and operation delay information was assessed from the Dan-
ish Multidisciplinary Hip Fracture Registry. Four categories 
comprising housing information were created: own accom-
modation, residential institution, homeless, and unknown. 
Likewise, four categories based on BMI values were cre-
ated: underweight (BMI <18.5 kg/m2), normal weight (BMI 
≥18.5 <25 kg/m2), overweight or obese (BMI ≥25 kg/m2), 
and unknown. Age, gender, and marital status were obtained 
from the Danish Civil Registration System. Comorbidities 
were identified using the Danish National Patient Registry. 
Overall comorbidity was summarized according to the origi-
nal Charlson Comorbidity Index (CCI) score. The CCI was 
categorized as low (score 0), medium (score 1–2), and high 
(score ≥3) comorbidity score, slightly modified compared 
with the original CCI.21 The following medications were 
assessed from the Danish National Database of Reimbursed 
Prescriptions: non-steroidal anti-inflammatory drugs, corti-
costeroids, anticoagulants, statins, non-SSRI antidepressants, 
and antipsychotics. Use of each medication was defined as 
follows: current users redeemed one prescription within 90 
days, former users redeemed one prescription between 91 and 
365 days, and non-users redeemed no prescriptions within 
365 days before hip fracture surgery. All codes defining study 
variables are available in Tables S1–S3.
Statistical methods
Main analyses
Patient characteristics were tabulated according to SSRI 
use. All patients were followed from operation date to death, 
any unplanned readmission, any reoperation, cardiovascular 
event, bleeding event, or up to 30 days. Kaplan–Meier curves 
of the three SSRI exposure groups were plotted depicting the 
absolute mortality risk over time. The cumulative incidence 
of postoperative complications was estimated treating death 
as a competing risk. Crude and adjusted HRs with 95% CIs 
of death and postoperative complications within 30 days were 
estimated using Cox regression analysis comparing current 
and former SSRI users with non-users. The mortality model 
was evaluated for effect modification by age and gender. 
Readmission outcome data were only available for patients 
operated on from January 1, 2011 onward, thus readmission 
analyses were restricted to patients operated on between 
January 1, 2011 and December 31, 2016. RRs of quality 
of in-hospital care were estimated using Poisson regression 
analysis. The process-performance measures representing 
quality of in-hospital care were introduced in the Danish 
Multidisciplinary Hip Fracture Registry at various times. 
Therefore, the analyses regarding the quality of in-hospital 
care were performed only in hip fracture patients operated on 
between January 1, 2015 and December 31, 2016. Potential 
confounder assessment was done using a directed acyclic 
graph (Figure S1).22 All adjusted analyses accounted for age, 
gender, marital status, operation year, comorbidities, other 
medication, and clustering by unit setting.
sensitivity analysis
Two sensitivity analyses were performed to test the robustness 
of the results. First, missing BMI values were imputed using 
multiple imputation (Supplementary materials).23 Missing 
housing data were not imputed due to lack of predictors. Sec-
ond, the exposure definition was changed to address potential 
compliance problems; current SSRI users redeemed two 
prescriptions within 2 years, of which one prescription was 
redeemed within 8 months before hip fracture, former users 
redeemed two prescriptions between 8 months and 2 years, 
and non-users redeemed one or no prescriptions within 2 
years before hip fracture. The mortality analysis was repeated 
including BMI in the Cox regression model and employing a 
new exposure definition. Cox and Poisson regression analyses 
were performed using Stata 14 for Windows (StataCorp LP, 
College Station, TX, USA). The Kaplan–Meyer plot was 
produced using R for Windows 3.4.2 (The R Foundation for 
Statistical Computing, Vienna, Austria).
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Results
Patient characteristics
We identified 68,487 first-time hip fracture patients between 
2006 and 2016. Of these, 13,272 (19%) were current SSRI 
users, 2,777 (4%) former, and 52,438 (77%) non-users. Table 
1 presents the patient characteristics according to SSRI use. 
The median patient age was 84 years in current users (IQR 
78–89 years) and 83 years in former users (IQR 77–88 years) 
and non-users (IQR 77–89 years). The current and former 
SSRI users had higher overall comorbidity than non-users, as 
well as higher prevalence of cerebrovascular disease, demen-
tia, use of non-SSRI antidepressants, and antipsychotics. 
Current SSRI users had a higher prevalence of anticoagulant 
use than both former users and non-users (Table 1).
In total, 13,295 patients (19%) were missing BMI data 
and 30,285 (44%) patients were missing housing data. From 
the available housing data, we observed that SSRI non-users 
(25,537 [49%]) more often lived in their own accommoda-
tion compared with current (4,412 [33%]) and former (1,126 
[41%]) users. However, there was no difference in BMI 
distribution between the exposure groups (Table 1).
Mortality
Overall, 7,295 hip fracture patients died within the first 30 
days following hip fracture surgery. Mortality was higher 
in current (13%) and former (12%) users compared with 
non-users (10%) (Figure 1 and Table 2). Compared with non-
users, the adjusted HR was 1.16 (1.10–1.21) in current users 
and 1.15 (1.04–1.27) in former users (Table 2). We found no 
effect modification by age and gender of the relation between 
SSRI use and mortality.
readmission and reoperation
Table 2 shows cumulative incidences and HRs of any unplanned 
readmission and any reoperation within 30 days postoperatively. 
In total, 6,208 of 36,356 were readmitted and 2,327 of 68,487 
re-operated within 30 days after surgery. Both current (HR 1.11, 
1.02–1.20) and former users (HR 1.13, 1.01–1.27) had a higher 
readmission risk compared with non-users. Current SSRI users 
had a higher reoperation risk (HR 1.21, 1.11–1.31) compared 
with non-users while there was no difference between former 
users (HR 1.04, 0.84–1.28) and non-users.
Other postoperative complications
During the first 30 days following hip fracture surgery, 573 
patients experienced VTE, 546 MI, 863 stroke, and 1,011 
major bleeding. Table 2 shows cumulative incidences and 
HRs of the individual complications. Current SSRI users had 
a similar risk of VTE (HR 0.89, 0.67–1.17), MI (HR 1.03, 
0.81–1.30), stroke (HR 0.93, 0.80–1.09), and bleeding (HR 
1.06, 0.89–1.28) as non-users. Likewise, former SSRI users 
had a similar risk of VTE (HR 0.93, 0.64–1.35), MI (HR 
0.89, 0.57–1.40), stroke (HR 0.67, 0.44–1.01), and bleeding 
(HR 1.06, 0.69–1.64) as non-users.
Quality of in-hospital care
The analyses included 11,363 patients operated on during 
2015–2016. Figure 2 shows a marginally higher chance of 
assessment of basic mobility at discharge, osteoporosis pro-
phylaxis, and future fall prophylaxis in former SSRI users 
compared with non-users. Overall, there was no association 
between current and former SSRI use and quality of in-
hospital care (Table S4).
sensitivity analysis
The HRs of mortality did not materially change after mul-
tiple imputation of missing BMI values and adjustment for 
BMI (Tables S5 and S6). Changing the exposure definition, 
we identified 14,530 (21%) current SSRI users, 1,116 (2%) 
former users, and 52,841 (77%) non-users. Patient char-
acteristics in the new exposure groups were similar to the 
patient characteristics of the exposure groups used in the 
main analysis and the HRs of mortality were similar to the 
main analysis results (Tables S7 and S8).
Discussion
In this nationwide cohort study of hip fracture surgery 
patients, 30-day mortality and overall readmission were ele-
vated for both current and former SSRI users. Those currently 
using SSRIs had an increased reoperation risk compared 
with non-users. However, SSRI use was not associated with 
increased risk of cardiovascular and bleeding complications 
and inferior quality of in-hospital care.
strengths and limitations
The strengths of this study are the use of well-established, 
well-validated, and prospectively collected data from Danish 
population-based registries with complete follow-up.19,24–26 
The registries originate from a tax-supported and uniformly 
organized health care system, reducing the risk of selection 
bias. The validity of the hip fracture diagnosis is high,27,28 
and the complete follow-up reduces the risk of differential 
misclassification. In general, our study included all elderly 
hip fracture patients aged 65 years or older in Denmark 
between 2006 and 2016. These patients are similar regard-
ing age and gender to those included in other studies on hip 
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Table 1 Baseline characteristics of hip fracture patients (n=68,487) according to preoperative selective serotonin reuptake inhibitor 
use 2006–2016
Characteristics All patients 
(N=68,487)
SSRI status
Current users 
(N=13,272)
Former users  
(N=2,777)
Non-users 
(N=52,438)
n % n % n % n %
Age (years)
65–74 13,271 19.4 10,571 20.2 533 19.2 2,167 16.3
75–84 26,086 38.1 19,768 37.7 1,159 41.7 5,159 38.9
≥85 29,130 42.5 22,099 42.1 1,085 39.1 5,946 44.8
Gender
Male 19,750 28.8 15,541 29.6 730 26.3 3,479 26.2
Female 48,737 71.2 36,897 70.4 2,047 73.7 9,793 73.8
Marital status
Married 20,300 29.6 16,105 30.7 842 30.3 3.353 25.3
Unmarried 48,187 70.4 36,333 69.3 1,935 69.7 9,919 74.7
Housing
Own accommodation 31,075 45.4 25,537 48.7 1,126 40.5 4,412 33.2
homeless 22 <0.1 20 0.1 0 0.0 2 <0.1
residential institution 7,105 10.4 4,213 8.0 408 14.7 2,484 18.7
Unknown 30,285 44.2 22,668 43.2 1,243 44.8 6,374 48.0
Fracture type
Fracture of femoral neck 36,341 53.1 27,854 53.1 1,451 52.3 7,036 53.0
Per- and subtrochanteric fracture 32,146 46.9 24,584 46.9 1,326 47.7 6,236 46.9
Operation type
alloplastic surgery 46,859 68.4 35,843 68.4 1,902 68.5 9,114 68.7
Osteosynthesis 21,628 31.6 16,595 31.6 875 31.5 4,158 31.3
Operation delay (hours)
<24 41,671 60.8 31,859 60.8 1,721 62.0 8,091 61.0
24–48 12,517 18.3 9,646 18.4 461 16.6 2,410 18.1
>48 14,299 20.9 10,933 20.8 595 21.4 2,771 20.9
Operation year
2006–2010 32,131 46.9 23,822 45.4 1,342 48.3 6,967 52.5
2011–2016 36,356 53.1 28,616 54.6 1,435 51.7 6,305 47.5
BMI (kg/m2)
<18.5: underweight 5,988 8.8 4,558 8.7 292 10.5 1,138 8.6
≥18.5 <25: normal weight 31,582 46.1 24,390 46.5 1,254 45.2 5,938 44.7
≥25: overweight or obese 17,622 25.7 13,602 25.9 689 24.8 3,331 25.1
Unknown 13,295 19.4 9,888 18.9 542 19.5 2,865 21.6
Charlson Comorbidity Index
low (0) 27,283 39.8 22,505 42.9 840 30.3 3,938 29.7
Medium (1–2) 27,787 40.6 20,365 38.8 1,244 44.8 6,178 46.5
high (3+) 13,417 19.6 9,568 18.3 693 24.9 3,156 23.8
Comorbidity
Myocardial infarction 3,762 5.5 2,820 5.4 151 5.4 791 6.0
Congestive heart failure 6,289 9.2 4,632 8.8 291 10.5 1,366 10.3
Peripheral vascular disease 5,511 8.1 4,060 7.7 267 9.6 1,184 8.9
Cerebrovascular disease 12,678 18.5 8,467 16.2 689 24.8 3,522 26.5
Dementia 6,733 9.8 3,859 7.4 433 15.6 2,441 19.4
Chronic pulmonary disease 8,663 12.7 6,191 11.8 496 17.9 1,976 14.9
Connective tissue disease 3,243 4.7 2,480 4.7 139 5.0 624 4.7
Ulcer disease 3,855 5.6 2,673 5.1 224 8.1 958 7.2
liver disease 870 1.3 646 1.2 46 1.7 178 1.3
Diabetes type 1 and 2 6,689 9.8 5,005 9.5 281 10.1 1,403 10.6
hemiplegia 175 0.3 111 0.2 12 0.4 52 0.4
Moderate to severe renal disease 2,688 3.9 1,973 3.4 132 4.8 583 4.4
Cancer 10,957 16.0 8,351 15.9 501 18.0 2,105 15.9
(Continued)
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fractures in the elderly.4,7 To date, this is the largest study 
examining the association between SSRI use and mortality, 
postoperative complications, and quality of in-hospital care 
in hip fracture patients.
We gathered comprehensive data on potential confound-
ers including complete in-hospital comorbidity history com-
piled in the CCI26 and history of specific diseases. However, 
we did not have information on the severity of diseases 
included in the CCI, on diseases treated in primary care, 
which were not severe enough to warrant a hospital diagno-
sis, or information on the underlying disease indication for 
SSRI prescription. However, we included information on 
Table 1 (Continued)
Characteristics All patients 
(N=68,487)
SSRI status
Current users 
(N=13,272)
Former users  
(N=2,777)
Non-users 
(N=52,438)
n % n % n % n %
nsaiDs 7,681 11.2 5,869 11.2 334 12.0 1,478 11.1
Corticosteroids 4,158 6.1 3,068 5.9 186 6.7 904 6.8
anticoagulants 26,716 39.0 19,323 36.9 1,064 38.3 6,329 47.7
statins 13,052 19.1 9,581 18.3 505 19.2 2,966 22.4
non-ssri antidepressants 7,975 11.6 4,977 9.5 596 21.5 2,402 18.1
antipsychotics 4,992 7.3 2,899 5.5 319 11.5 1,774 13.4
Abbreviations: SSRI, selective serotonin reuptake inhibitor; NSAIDs, non-steroidal anti-inflammatory drugs.
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Figure 1 Kaplan–Meyer survival curve showing mortality in hip fracture patients according to selective serotonin reuptake inhibitor (ssri) use 2006–2016.
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other medication, which may indicate treatment of condi-
tions not captured in the CCI. The registries we used did 
not contain information on socioeconomic status, smoking, 
alcohol use, and other lifestyle factors. Furthermore, almost 
half of the patients were missing data on housing, making 
control of confounding difficult. Thus, we were not able to 
control for the potential confounding of social deprivation 
and lack of these data may have resulted in unmeasured and 
residual confounding. Information on comorbidities, other 
medication, marital status, and unit setting may contribute 
to control of confounding, but is not an adequate measure 
of social deprivation.
We included former SSRI users as a negative control. 
That is, we anticipated that former users were more similar to 
current users than non-users regarding potential confounding 
factors such as socioeconomic status and lifestyle factors. 
Thus, if the effect of SSRI exposure on mortality was caused 
by the medication itself, we would anticipate only seeing 
an effect in current users and not in former users. However, 
this was not the case, and the observed association between 
SSRI use and mortality may rather be caused by underlying 
risk factors.29
We did not have information about compliance. In our 
study, non-compliance would cause a misclassification of 
non-users as users, and therefore the observed association 
between SSRI use and mortality, readmission, or reopera-
tion risk might actually be higher. However, as the patients 
redeemed the prescriptions, our estimates most likely reflect 
actual drug use. Even considering misclassification, dis-
pensed prescriptions are considered a good measure of medi-
cation intake.30 Furthermore, we had no data on in-hospital 
medication use. This may not have influenced the outcome 
Table 2 Cumulative incidences and hrs with 95% Cis of mortality, readmission, reoperation, and postoperative complications within 
30 days of hip fracture surgery according to selective serotonin reuptake inhibitor (ssri) use 2006–2016 (n=68,487)
Event/total Incidence %
(95% CI)
Unadjusted HR
(95% CI)
Adjusteda HR
(95% CI)
Mortality
Current users 1,755/13,272 13.2 (12.7–12.8) 1.35 (1.28–1.43) 1.16 (1.10–1.21)
Former users 338/2,777 12.2 (11.0–12.5) 1.24 (1.11–1.38) 1.15 (1.04–1.27)
non-users 5,202/52,438 9.9 (9.7–10.2) 1.00 1.00
Readmissionb
Current users 1,192/6,305 19.0 (18.0–19.9) 1.21 (1.14–1.29) 1.11 (1.02–1.20)
Former users 280/1,435 19.6 (17.5–21.6) 1.24 (1.10–1.40) 1.13 (1.01–1.27)
non-users 4,642/28,616 16.3 (15.8–16.7) 1.00 1.00
Reoperation
Current users 749/13,272 5.6 (5.3–6.0) 1.29 (1.18–1.40) 1.21 (1.11–1.31)
Former users 135/2,777 4.9 (4.1–5.7) 1.10 (0.92–1.30) 1.04 (0.84–1.28)
non-users 2,353/52,438 4.5 (4.3–4.7) 1.00 1.00
VTE
Current users 96/13,272 0.7 (0.6–0.9) 0.85 (0.68–1.06) 0.89 (0.67–1.17)
Former users 22/2,777 0.8 (0.5–1.7) 0.92 (0.60–1.42) 0.93 (0.64–1.35)
non-users 455/52,438 0.9 (0.8–0.9) 1.00 1.00
MI
Current users 109/13,272 0.8 (0.7–1.0) 1.04 (0.84–1.28) 1.03 (0.81–1.30)
Former users 18/2,777 0.6 (0.4–1.0) 0.82 (0.51–1.31) 0.89 (0.57–1.40)
non-users 419/52,438 0.8 (0.7–0.9) 1.00 1.00
Stroke
Current users 176/13,272 1.3 (1.1–1.5) 1.06 (0.90–1.25) 0.93 (0.80–1.09)
Former users 25/2,777 0.9 (0.6–1.3) 0.72 (0.48–1.07) 0.67 (0.44–1.01)
non-users 662/52,438 1.3 (1.2–1.4) 1.00 1.00
Bleeding
Current users 218/13,272 1.6 (1.4–1.9) 1.17 (1.01–1.36) 1.06 (0.89–1.28)
Former users 43/2,777 1.5 (1.1–2.1) 1.09 (0.81–1.49) 1.06 (0.69–1.64)
non-users 750/52,438 1.4 (1.3–1.5) 1.00 1.00
Notes: aadjusted for age, gender, marital status, operation year, Mi, congestive heart failure, peripheral vascular disease, dementia, chronic pulmonary disease, connective 
tissue disease, ulcer disease, liver disease, diabetes type 1 and 2, hemiplegia, moderate to severe renal disease, cancer, non-steroidal anti-inflammatory drugs, corticosteroids, 
anticoagulants, statins, non-ssri antidepressants, antipsychotics, and clustering by unit setting. brestricted to hip fracture patients operated on between 2011 and 2016.
Abbreviations: VTE, venous thromboembolism; Mi, myocardial infarction.
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since hip fracture surgery is an acute procedure with short 
length of hospital stay.
Comparison with other studies
We observed an equally increased mortality risk in current 
and former SSRI users. This suggests that rather than being a 
risk factor in itself, SSRI use may be a marker of underlying 
risk factors such as psychiatric illness, socioeconomic status, 
and lifestyle factors (smoking, alcohol misuse, and physical 
inactivity). These results are consistent with those obtained 
by Auerbach et al, showing an increased mortality in SSRI 
users compared with non-users after major surgery, includ-
ing approximately 2% hip fracture surgeries.12 However, the 
association found by Auerbach et al was attenuated in patients 
with depression suggesting that the underlying psychiatric 
indication for SSRI use may explain the increased risk rather 
than SSRIs in itself.12 A meta-analysis by Maslej et al found 
an increased mortality in antidepressant users compared to 
non-users in the general population independent of treatment 
indication.31 The most common indications for SSRI treat-
ment are depression and anxiety10 and a systematic review 
by Eaton et al showed that depression and anxiety correlate 
with increased mortality.32 Mortality in hip fracture patients 
may also be influenced by socioeconomic status,33 and 
Marinacci et al found an association between lower educa-
tion level and mortality.34 Lower education level is further 
associated with increased risk of psychiatric admission due 
to schizophrenia, alcoholism, drug dependency, affective 
psychosis, neurosis, and personality disorder.35 Finally, Seitz 
et al found no difference in 30-day mortality between cur-
rent (9.1%) and former (9.4%) serotonergic antidepressant 
users undergoing hip fracture surgery.36 However, they did 
not include a non-user group, which distorts the association 
between SSRI use and mortality.
Our findings of an increased overall readmission risk in 
current and former SSRI users compared with non-users 
is consistent with the findings reported by Auerbach et al 
in major surgery patients. In their study, this association 
persisted in patients receiving SSRIs for depression, but 
not in patients receiving SSRIs for other reasons.12 This 
Preoperative optimization
Operation within 24 hours
Operation within 36 hours
Mobilization within 24 hours
Basic mobility at admission
Basic mobility at discharge
Nutritional risk assessment
Osteoporotic prophylaxis
Future fall prophylaxis
0.90 0.95 1.00
RR (95% CI)
SSRI status
Current users
Former users
1.05 1.10
Figure 2 adjusted rrs with 95% Cis of quality of in-hospital care comparing current and former selective serotonin reuptake inhibitor (ssri) users with non-users 
(reference) 2015–2016 (n=11,363).
Notes: adjusted for age, gender, marital status, operation year, myocardial infarction, congestive heart failure, peripheral vascular disease, dementia, chronic pulmonary 
disease, connective tissue disease, ulcer disease, liver disease, diabetes type 1 and 2, hemiplegia, moderate to severe renal disease, cancer, non-steroidal anti-inflammatory 
drugs, corticosteroids, anticoagulants, statins, non-ssri antidepressants, antipsychotics, and clustering by unit setting.
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also suggests that SSRI use may not be a risk factor in itself 
but a marker of underlying disease or risk factors. A meta-
analysis by Pizzi et al found no association between SSRI 
use and readmission in patients with coronary heart disease 
and depression, further supporting our results that SSRI use 
may not be a risk factor in itself.37
Another important finding was that current SSRI users 
had an increased reoperation risk compared with non-users, 
whereas the risk was not elevated in former users. A possible 
explanation for this could be that SSRI use may increase the 
likelihood of complications necessitating reoperation. There 
are different reasons for performing reoperation, eg, wound 
dehiscence, infection, and bleeding,20 and these complications 
may be more frequent in SSRI users. Gärtner et al found an 
association between SSRI use and reoperation due to bleed-
ing after breast cancer surgery.38 However, Tully et al showed 
no association between serotonergic antidepressant use and 
reoperation due to infection or bleeding after coronary artery 
bypass graft surgery.39 Further research is needed to establish 
the association between SSRI use and reoperation risk due 
to different causes in hip fracture patients.
We found little evidence of an association between 
SSRI and the risk of VTE, MI, stroke, and bleeding. To our 
knowledge, no other studies have investigated the association 
between SSRI use and the previously mentioned postopera-
tive complications following hip fracture surgery. Auerbach 
et al found an association between SSRI use and postopera-
tive bleeding in major surgery patients. However, they had 
a broader bleeding definition, including bleeding following 
procedure, and they included both acute and elective opera-
tions.12 Tully et al showed no association between SSRI use 
and MI, stroke, or bleeding after coronary artery bypass graft 
surgery,39 supporting our findings.
The present study did not find any difference between 
SSRI non-users and users regarding quality of in-hospital care. 
This is important and in line with efforts of European govern-
ments to reduce social inequality in treatment of patients.40 
However, we have no information on quality of patient care 
outside hospital settings. Previous research suggests lower 
30-day mortality in hip fracture patients who received higher 
quality of care.5 Quality of in-hospital care may not explain 
the increased mortality associated with SSRI use in our study.
Implications of findings
One issue emerging from our findings is the question about 
discontinuation of SSRI treatment after hip fracture surgery. 
Since hip fracture is an acute condition, it is not possible to stop 
treatment before surgery. Our analysis suggests that stopping 
SSRI treatment after surgery would not change the mortality 
and overall readmission since these were similar in current 
and former users compared with non-users. We found that 
overall reoperation was augmented in current users, but not 
in former users compared with non-users. However, pausing 
SSRI treatment without a complete discussion of the risks and 
benefits is unwarranted. Our findings call for increased clinical 
awareness of hip fracture patients using SSRIs as they may 
have an increased risk of mortality, unplanned readmission, and 
reoperation. This patient group may be more prone to adverse 
outcomes after surgery regardless of the indication for SSRI 
treatment and may benefit from improved models of care. The 
follow-up care in Denmark is carried out by the municipality. 
Our findings suggest that hip fracture patients currently or 
formerly using SSRIs may benefit from closer follow-up and 
better communication between hospital, municipality, and 
general practitioner. However, the content and implementation 
of such improvements are beyond the scope of this paper. In 
future studies, it may be relevant to investigate how social 
deprivation influences surgical outcomes for these patients.
Conclusion
Thirty-day mortality and overall readmission in hip fracture 
patients were elevated in both current and former SSRI users 
compared with non-users. Those currently using SSRIs had 
an increased overall reoperation risk compared with non-
users. However, SSRI use was not associated with increased 
risk of cardiovascular and bleeding complications and lower 
quality of in-hospital care.
Data availability
The authors are not authorized to share the data as it were 
assessed via the data custodian, ie, the Danish National Data 
Board.
Acknowledgments
We thank the staff of the hospital departments caring for 
patients with hip fracture for their continuous effort and 
contribution to acquisition of the data in the Danish Multi-
disciplinary Hip Fracture Registry. The Independent Research 
Fund Denmark (grant number 6120–00034) funded this 
work. The funder had no role in the study design; in the col-
lection, analysis, and interpretation of data; in the writing 
of the report; and in the decision to submit the article for 
publication. The researchers are independent from the funder. 
The study results were presented at the Danish Orthopedic 
Society Congress in October 2017 and at the PhD Day at 
Aarhus University in January 2018.
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
41
.3
5.
55
 o
n 
19
-S
ep
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2018:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1062
Bruun et al
Author contributions
All authors made substantial contributions to conception and 
design, acquisition of data, or analysis and interpretation of 
data; took part in drafting the article or revising it critically 
for important intellectual content; gave final approval of the 
version to be published; and agree to be accountable for all 
aspects of the work.
Disclosure
The authors report no conflicts of interest in this work.
References
 1. Requena G, Abbing-Karahagopian V, Huerta C, et al. Incidence 
rates and trends of hip/femur fractures in five European countries: 
comparison using e-healthcare records databases. Calcif Tissue Int. 
2014;94(6):580–589.
 2. Polinder S, Meerding WJ, van Baar ME, et al. Cost estimation of 
injury-related hospital admissions in 10 European countries. J Trauma. 
2005;59(6):1283-1290.
 3. de Luise C, Brimacombe M, Pedersen L, Sørensen HT. Comorbidity 
and mortality following hip fracture: a population-based cohort study. 
Aging Clin Exp Res. 2008;20(5):412–418.
 4. Roche JJ, Wenn RT, Sahota O, Moran CG. Effect of comorbidi-
ties and postoperative complications on mortality after hip fracture 
in elderly people: prospective observational cohort study. BMJ. 
2005;331(7529):1374.
 5. Nielsen KA, Jensen NC, Jensen CM, et al. Quality of care and 30 day 
mortality among patients with hip fractures: a nationwide cohort study. 
BMC Health Serv Res. 2009;9:186.
 6. Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox 
J. Antidepressant use and risk of adverse outcomes in older people: 
population based cohort study. BMJ. 2011;343:d4551.
 7. Lawrence VA, Hilsenbeck SG, Noveck H, Poses RM, Carson JL. Medi-
cal complications and outcomes after hip fracture repair. Arch Intern 
Med. 2002;162(18):2053–2057.
 8. Vieira ER, Palmer RC, Chaves PH. Prevention of falls in older people 
living in the community. BMJ. 2016;353:i1419.
 9. Medstat.dk [homepage on the Internet]. The Danish Health Data Author-
ity. Available from: http://medstat.dk/. Accessed July 5, 2018.
 10. Noordam R, Aarts N, Verhamme KM, Sturkenboom MC, Stricker BH, 
Visser LE. Prescription and indication trends of antidepressant drugs in 
the Netherlands between 1996 and 2012: a dynamic population-based 
study. Eur J Clin Pharmacol. 2015;71(3):369–375.
 11. Wu CS, Chang CM, Chen CY, et al. Association between antidepressants 
and venous thromboembolism in Taiwan. J Clin Psychopharmacol. 
2013;33(1):31–37.
 12. Auerbach AD, Vittinghoff E, Maselli J, Pekow PS, Young JQ, Linde-
nauer PK. Perioperative use of selective serotonin reuptake inhibi-
tors and risks for adverse outcomes of surgery. JAMA Intern Med. 
2013;173(12):1075–1081.
 13. Movig KL, Janssen MW, de Waal Malefijt J, Kabel PJ, Leufkens HG, 
Egberts AC. Relationship of serotonergic antidepressants and need for 
blood transfusion in orthopedic surgical patients. Arch Intern Med. 
2003;163(19):2354–2358.
 14. van Haelst IM, Egberts TC, Doodeman HJ, et al. Use of serotonergic 
antidepressants and bleeding risk in orthopedic patients. Anesthesiology. 
2010;112(3):631–636.
 15. Statistics Denmark. Statistical Yearbook. 121th ed. Copenhagen: Sta-
tistics Denmark; 2017.
 16. Sørensen HT, Christensen T, Schlosser HK, Pedersen L. Use of Medi-
cal Databases in Clinical Epidemiology. 2nd ed. Aarhus: SUN-TRYK, 
Aarhus Universitet; 2009.
 17. Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration 
System as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541–549.
 18. Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, 
Sørensen HT. The Danish National Patient Registry: a review of content, 
data quality, and research potential. Clin Epidemiol. 2015;7:449–490.
 19. Johannesdottir SA, Horváth-Puhó E, Ehrenstein V, Schmidt M, Pedersen 
L, Sørensen HT. Existing data sources for clinical epidemiology: The 
Danish National Database of Reimbursed Prescriptions. Clin Epidemiol. 
2012;4:303–313.
 20. Centre for Clinical Epidemiology and Biostatistics North. The Danish 
Multidisciplinary Hip Fracture Register - National Annual Report 2017: 
The Danish Clinical Registries; 2017. Available from: https://www.sund-
hed.dk/content/cms/62/4662_hofte-fraktur-%C3%A5rsrapport_2017.
pdf. Accessed August 7, 2018. Danish.
 21. Charlson ME, Pompei P, Ales KL, Mackenzie CR. A new method of 
classifying prognostic comorbidity in longitudinal studies: development 
and validation. J Chronic Dis. 1987;40(5):373–383.
 22. Shrier I, Platt RW. Reducing bias through directed acyclic graphs. BMC 
Med Res Methodol. 2008;8(1):70.
 23. Pedersen AB, Mikkelsen EM, Cronin-Fenton D, et al. Missing data 
and multiple imputation in clinical epidemiological research. Clin 
Epidemiol. 2017;9:157–166.
 24. Sundbøll J, Adelborg K, Munch T, et al. Positive predictive value of 
cardiovascular diagnoses in the Danish National Patient Registry: a 
validation study. BMJ Open. 2016;6(11):e012832.
 25. Wildenschild C, Mehnert F, Thomsen RW, et al. Registration of acute 
stroke: validity in the Danish Stroke Registry and the Danish National 
Registry of Patients. Clin Epidemiol. 2014;6:27–36.
 26. Thygesen SK, Christiansen CF, Christensen S, Lash TL, Sørensen 
HT. The predictive value of ICD-10 diagnostic coding used to assess 
Charlson comorbidity index conditions in the population-based Danish 
National Registry of Patients. BMC Med Res Methodol. 2011;11:83.
 27. Baron JA, Lu-Yao G, Barrett J, Mclerran D, Fisher ES. Internal valida-
tion of Medicare claims data. Epidemiology. 1994;5(5):541–544.
 28. Hudson M, Avina-Zubieta A, Lacaille D, Bernatsky S, Lix L, Jean S. 
The validity of administrative data to identify hip fractures is high--a 
systematic review. J Clin Epidemiol. 2013;66(3):278–285.
 29. Lawlor DA, Tilling K, Davey Smith G. Triangulation in aetiological 
epidemiology. Int J Epidemiol. 2016;45(6):1866–1886.
 30. Schneeweiss S, Avorn J. A review of uses of health care utilization 
databases for epidemiologic research on therapeutics. J Clin Epidemiol. 
2005;58(4):323–337.
 31. Maslej MM, Bolker BM, Russell MJ, et al. The mortality and myocar-
dial effects of antidepressants are moderated by preexisting cardiovas-
cular disease: a meta-analysis. Psychother Psychosom. 2017;86(5): 
268–282.
 32. Eaton WW, Martins SS, Nestadt G, Bienvenu OJ, Clarke D, Alexandre 
P. The burden of mental disorders. Epidemiol Rev. 2008;30:1–14.
 33. Thorne K, Johansen A, Akbari A, Williams JG, Roberts SE. The 
impact of social deprivation on mortality following hip fracture in 
England and Wales: a record linkage study. Osteoporos Int. 2016;27(9): 
2727–2737.
 34. Marinacci C, Grippo F, Pappagallo M, et al. Social inequalities in total 
and cause-specific mortality of a sample of the Italian population, from 
1999 to 2007. Eur J Public Health. 2013;23(4):582–587.
 35. Tiikkaja S, Sandin S, Malki N, Modin B, Sparén P, Hultman CM. Social 
class, social mobility and risk of psychiatric disorder--a population-
based longitudinal study. PLoS One. 2013;8(11):e77975.
 36. Seitz DP, Bell CM, Gill SS, et al. Risk of perioperative blood transfu-
sions and postoperative complications associated with serotonergic 
antidepressants in older adults undergoing hip fracture surgery. J Clin 
Psychopharmacol. 2013;33(6):790–798.
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
41
.3
5.
55
 o
n 
19
-S
ep
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2018:10 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1063
ssri use and adverse outcomes in hip fracture patients
 37. Pizzi C, Rutjes AW, Costa GM, Fontana F, Mezzetti A, Manzoli 
L. Meta-analysis of selective serotonin reuptake inhibitors in 
patients with depression and coronary heart disease. Am J Cardiol. 
2011;107(7):972–979.
 38. Gärtner R, Cronin-Fenton D, Hundborg HH, et al. Use of selective sero-
tonin reuptake inhibitors and risk of re-operation due to post-surgical 
bleeding in breast cancer patients: a Danish population-based cohort 
study. BMC Surg. 2010;10:3.
 39. Tully PJ, Cardinal T, Bennetts JS, Baker RA. Selective serotonin reuptake 
inhibitors, venlafaxine and duloxetine are associated with in hospital 
morbidity but not bleeding or late mortality after coronary artery bypass 
graft surgery. Heart Lung Circ. 2012;21(4):206–214.
 40. World Health Organization Europe. Parma Declaration on Environment 
and Health. Fifth Ministerial Conference on Environment and Health. 
Parma, Italy; 2010. Available from: http://www.euro.who.int/__data/
assets/pdf_file/0011/78608/E93618.pdf. Accessed August 07, 2018.
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
41
.3
5.
55
 o
n 
19
-S
ep
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2018:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1064
Bruun et al
Supplementary materials
Table S1 iCD-8 and iCD-10 diagnosis codes from the Danish national Patient registry
Variable Codes
Disease ICD-8 diagnosis codes ICD-10 diagnosis codes
Myocardial infarction 410 i21; i22; i23
Congestive heart failure 427.09; 427.10; 427.11; 427.19; 
428.99; 782.49
i50; i11.0; i13.0; i13.2
Peripheral vascular disease 440; 441; 442; 443; 444; 445 i70; i71; i72; i73; i74; i77
Cerebrovascular disease 430–438 i60-i69; g45; g46 
Dementia 290.09–290.19; 293.09 F00-F03; F05.1; g30
Chronic pulmonary 
disease
490–493; 515–518 J40-J47; J60-J67; J68.4; J70.1; J70.3; 
J84.1; J92.0; J96.1; J98.2; J98.3
Connective tissue disease 712; 716; 734; 446; 135.99 M05; M06; M08; M09; M30; M31; 
M32; M33; M34; M35; M36; D86
Ulcer disease 530.91; 530.98; 531–534 K22.1; K25-K28
liver disease 571; 573.01; 573.04; 070.00; 070.02; 
070.04; 070.06; 070.08; 573.00; 
456.00–456.09
B18; K70.0-K70.3; K70.9; K71; K73; 
K74; K76.0; B15.0; B16.0; B16.2; 
B19.0; K70.4; K72; K76.6; i85
Diabetes type 1 and type 2 249.00; 249.06; 249.07; 249.09 250.00; 
250.06; 250.07; 250.09; 249.01–
249.05; 249.08; 250.01–250.05; 250.08
E10.0, E10.1; E10.9 E11.0; E11.1; 
E11.9; E10.2-E10.8; E11.2-E11.8
hemiplegia 344 g81; g82 
Moderate to severe renal 
disease
403; 404; 580–583; 584; 590.09; 
593.19; 753.10–753.19; 792 
i12; i13; n00-n05; n07; n11; n14; 
n17-n19; Q61
Cancer 140–194; 204–207; 200–203; 275.59; 
195–198; 199
C00–C75; C91–C95; C81–C85; 
C88; C90; C96; C76–C80
intracranial bleeding i60–i62
Esophagus varices with 
bleeding
i850
hemothorax J942
acute ulcer with bleeding K250, K260, K270, K280
acute ulcer with bleeding 
and perforation
K252, K262, K272, K282
Chronic or non-specified 
ulcer with bleeding
K254, K264, K274, K284
Chronic or non-specified 
ulcer with bleeding and 
perforation
K256, K266, K276, K286
acute bleeding gastritis K290
Bleeding from anus or 
rectum
K625
gastrointestinal bleeding K920–K922
hematuria r31, n02
airway bleeding r04
Deep venous 
thromboembolism
i801–i803
lung embolism i26
acute myocardial 
infarction
i21
Brain infarction i63
Apoplexy, unspecified i64
Transitory cerebral 
infarction
g459
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Table S2 Codes from the Danish Multidisciplinary hip Fracture registry
Description Codes
Housing
Procedure code specifying housing ZZ8050
Own accommodation ZrsB01
Own accommodation in association with an institution ZrsB01a
homeless ZrsB02
residential institution ZrsB04
no information on housing ZrsB09
Fracture type
Fracture of the femoral neck s72.0
Pertrochanteric fracture s72.1
subtrochanteric fracture s72.2
Operation type
Primary insertion of joint prosthesis in hip joint KnFB.0–99
Fracture treatments in femur (including osteosynthesis) KnFJ.4–9
BMI
Procedure code determining BMi ZZ0242
BMi 10–80 VPh0010 – VPh0080
BMi 10–80 VPK10K00 – VPK80K00
Assessment of the patient’s nutritional risk
Preparation of nutritional plan ZZ2009C
assessment: no indication for preparation of nutritional plan ZZ2009D
Systematic pain assessment during mobilization of the patient
systematic assessment of pain using pain scale ZZV008a 
Pain assessment attempted: not possible ZZV008Z 
Early mobilization within 24 hours of surgery
Early mobilization commenced ZZP0030a 
assessed, no indication for early mobilization ZZP0030C 
Date of mobilization (eg, ZT20160602) ZTa
Time of mobilization (eg, ZU1430) ZUa
Assessment of basic mobility before admission for hip fracture
assessment of the basic mobility prior to fracture ZZV020g1 
Cumulated ambulation score (Cas) Zrra00 – Zrra09
Assessment of basic mobility before discharge
assessment of basic mobility at discharge ZZV020g2 
Cas Zrra00 – Zrra09
Initiation of rehabilitation program
Preparation of rehabilitation plan, general rehabilitation ZZ0175X
Preparation of rehabilitation plan, specialized rehabilitation ZZ0175Y
Preparation of rehabilitation plan, rehabilitation in the specialized level ZZ0175V
assessment of need for rehabilitation, no rehabilitation ZZ0172W
Osteoporosis prophylaxis
Treatment with medicine for osteoporosis BlhM7
Evaluation of the indication for drug therapy for osteoporosis ZZV010a1a
Pending complete investigation regarding indication for drug therapy for osteoporosis ZZV010a1X
Fall prophylaxis
Offer of fall prophylaxis given ZZ5707B1
assessment of need for fall prophylaxis: no indication ZZ5707a
Surgery delay
indicates the percentage of patients who are operated on within 24 hours of arrival at hospital 2a
indicates the percentage of patients who are operated on within 36 hours of arrival at hospital 2B
Note: anumber specifying the date or time of mobilization.
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Table S3 anatomical Therapeutic Chemical (aTC) codes from the Danish national Database of reimbursed Prescriptions
Selective serotonin reuptake inhibitor (SSRI) ATC codes
Citalopram n06aB04
Escitalopram n06aB10
Fluoxetine n06aB03
Fluvoxamine n06aB08
Paroxetine n06aB05
sertraline n06aB06
Other medication
non-ssri antidepressants n06aa, n06aF, n06ag, n06aX
antipsychotics n05a
antithrombotic medicine B01a
Non-steroidal anti-inflammatory drugs M01a
Corticosteroids h02aB
statins C10aa
Other_medication Operation_year
Fracture type
Operation_type
Operation_delay
Unit
Mortality
CCI
BMI
Housing
Marital_status
Gender
Age
SSRI
Figure S1 Directed acyclic graph of the possible relationship between important covariates and mortality in hip fracture patients.
Abbreviations: ssri, selective serotonin reuptake inhibitor; CCi, Charlson Comorbidity index.
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Table S4 Unadjusted and adjusted rrs with 95% Cis of quality of in-hospital care according to selective serotonin reuptake inhibitor 
(ssri) use 2015–2016 (n=11,363)
Fulfilment (%) Unadjusted RR (95% CI) Adjusteda RR (95% CI)
Preoperative optimization 4,301 (37.9)
Current user 649 (37.2) 0.98 (0.90–1.07) 1.00 (0.93–1.07)
Former user 161 (37.0) 0.97 (0.83–1.14) 0.97 (0.88–1.09)
non-user 3,491 (38.0) 1.00 1.00
Surgery within 24 hours 7,751 (68.2)
Current user 1,175 (67.4) 0.99 (0.93–1.05) 1.00 (0.97–1.04)
Former user 291 (66.9) 0.98 (0.87–1.10) 1.00 (0.94–1.06)
non-user 6,285 (68.4) 1.00 1.00
Surgery within 36 hours 9,641 (84.8)
Current user 1,471 (84.4) 0.99 (0.94–1.05) 1.00 (0.98–1.02)
Former user 354 (81.4) 0.96 (0.86–1.06) 0.97 (0.93–1.00)
non-user 7,816 (85.1) 1.00 1.00
Mobilization within 24 hours 6,483 (57.1)
Current user 952 (54.6) 0.95 (0.89–1.02) 0.99 (0.94–1.03)
Former user 249 (57.2) 1.00 (0.88–1.13) 1.03 (0.95–1.11)
non-user 5,282 (57.5) 1.00 1.00
Basic mobility at admission 10,383 (91.4)
Current user 1,569 (90.0) 0.98 (0.93–1.04) 0.99 (0.97–1.01)
Former user 402 (92.4) 1.01 (0.91–1.12) 1.02 (1.00–1.03)
non-user 8,412 (91.6) 1.00 1.00
Basic mobility at discharge 9,945 (87.5)
Current user 1,521 (97.3) 1.00 (0.94–1.05) 1.00 (0.99–1.02)
Former user 391 (89.9) 1.03 (0.93–1.14) 1.03 (1.01–1.06)
non-user 8,033 (87.5) 1.00 1.00
Nutritional status assessment 9,304 (81.9)
Current user 1,449 (83.1) 1.02 (0.96–1.08) 1.02 (0.99–1.06)
Former user 344 (79.1) 0.97 (0.87–1.08) 0.97 (0.91–1.03)
non-user 7,511 (81.8) 1.00 1.00
Osteoporosis prophylaxis 9,673 (85.1)
Current user 1,476 (84.7) 1.00 (0.94–1.05) 1.00 (0.98–1.03)
Former user 392 (90.1) 1.06 (0.96–1.17) 1.07 (1.03–1.11)
non-user 7,805 (85.0) 1.00 1.00
Future fall prophylaxis 9,402 (82.7)
Current user 1,431 (82.1) 0.99 (0.94–1.05) 1.00 (0.97–1.03)
Former user 380 (87.4) 1.06 (0.95–1.17) 1.06 (1.02–1.11)
non-user 7,591 (82.7) 1.00 1.00
Notes: aadjusted for age, gender, marital status, operation year, myocardial infarction, congestive heart failure, peripheral vascular disease, dementia, chronic pulmonary 
disease, connective tissue disease, ulcer disease, liver disease, diabetes type 1 and 2, hemiplegia, moderate to severe renal disease, cancer, non-steroidal anti-inflammatory 
drugs, corticosteroids, anticoagulants, statins, non-ssri antidepressants, antipsychotics, and clustering by unit setting. The numbers in bold represent the total number of 
patients fulfilling each process-performance measure.
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Sensitivity analyses
Multiple imputation
Methods
In the multiple imputation model, we included all variables 
that were in the subsequent analysis model: selective serotonin 
reuptake inhibitors (SSRIs), age, gender, marital status, opera-
tion year, BMI, comorbidities, and other medication. Further-
more, some auxiliary variables such as operation delay, fracture 
type, operation type, and postoperative complications were 
included. Imputation of BMI values was done using truncated 
regression creating 20 imputed datasets. After imputation, the 
association between SSRI use and mortality was estimated in 
each imputed dataset. The measures of association from each 
imputed dataset were combined using Rubin’s rule.
Table S5 Baseline characteristics of hip fracture patients (n=68,487) according to preoperative selective serotonin reuptake inhibitor 
(ssri) use 2006–2016 after imputation of BMi
Variables All patients SSRI
Non-users Former users Current users 
n % n % n % n %
Total 68,487 100 52,438 76.6 2,777 4.0 13,272 19.4
Median age (years) 83 83 83 84
Age (years)
65–74 13,271 19.4 10,571 20.2 533 19.2 2,167 16.3
75–84 26,086 38.1 19,768 37.7 1,159 41.7 5,159 38.9
≥85 29,130 42.5 22,099 42.1 1,085 39.1 5,946 44.8
Gender
Male 19,750 28.8 15,541 29.6 730 26.3 3,479 26.2
Female 48,737 71.2 36,897 70.4 2,047 73.7 9,793 73.8
Marital status
Married 20,300 29.6 16,105 30.7 842 30.3 3.353 25.3
Unmarried 48,187 70.4 36,333 69.3 1,935 69.7 9,919 74.7
Housing
Own accommodation 31,075 45.4 25,537 48.7 1,126 40.5 4,412 33.2
homeless 22 <0.1 20 0.1 0 0.0 2 <0.1
residential institution 7,105 10.4 4,213 8.0 408 14.7 2,484 18.7
Unknown 30,285 44.2 22,668 43.2 1,243 44.8 6,374 48.0
Fracture type
Fracture of femoral neck 36,341 53.1 27,854 53.1 1,451 52.3 7,036 53.0
Per- and subtrochanteric fracture 32,146 46.9 24,584 46.9 1,326 47.7 6,236 46.9
Operation type
alloplastic surgery 46,859 68.4 35,843 68.4 1,902 68.5 9,114 68.7
Osteosynthesis 21,628 31.6 16,595 31.6 875 31.5 4,158 31.3
Operation delay (hours)
<24 41,671 60.8 31,859 60.8 1,721 62.0 8,091 61.0
24–48 12,517 18.3 9,646 18.4 461 16.6 2,410 18.1
>48 14,299 20.9 10,933 20.8 595 21.4 2,771 20.9
Operation year
2006–2010 32,131 46.9 23,822 45.4 1,342 48.3 6,967 52.5
2011–2016 36,356 53.1 28,616 54.6 1,435 51.7 6,305 47.5
BMI (kg/m2)a
<18.5: underweight 7,672 11.2 5,806 11.1 357 12.9 1,509 11.4
≥18.5 <25: normal weight 35,397 51.7 27,163 51.8 1,440 51.8 6,794 51.2
≥25: overweight or obese 25,418 37.1 19,469 37.1 980 35.3 4,969 37.4
Charlson Comorbidity Index
low (0) 27,283 39.8 22,505 42.9 840 30.3 3,938 29.7
Medium (1–2) 27,787 40.6 20,365 38.8 1,244 44.8 6,178 46.5
high (3+) 13,417 19.6 9,568 18.3 693 24.9 3,156 23.8
(Continued)
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Table S5 (Continued)
Variables All patients SSRI
Non-users Former users Current users 
n % n % n % n %
Comorbidity
Myocardial infarction 3,762 5.5 2,820 5.4 151 5.4 791 6.0
Congestive heart failure 6,289 9.2 4,632 8.8 291 10.5 1,366 10.3
Peripheral vascular disease 5,511 8.1 4,060 7.7 267 9.6 1,184 8.9
Cerebrovascular disease 12,678 18.5 8,467 16.2 689 24.8 3,522 26.5
Dementia 6,733 9.8 3,859 7.4 433 15.6 2,441 19.4
Chronic pulmonary disease 8,663 12.7 6,191 11.8 496 17.9 1,976 14.9
Connective tissue disease 3,243 4.7 2,480 4.7 139 5.0 624 4.7
Ulcer disease 3,855 5.6 2,673 5.1 224 8.1 958 7.2
liver disease 870 1.3 646 1.2 46 1.7 178 1.3
Diabetes type 1 and 2 6,689 9.8 5,005 9.5 281 10.1 1,403 10.6
hemiplegia 175 0.3 111 0.2 12 0.4 52 0.4
Moderate to severe renal disease 2,688 3.9 1,973 3.4 132 4.8 583 4.4
Cancer 10,957 16.0 8,351 15.9 501 18.0 2,105 15.9
Other medication
nsaiDs 7,681 11.2 5,869 11.2 334 12.0 1,478 11.1
Corticosteroids 4,158 6.1 3,068 5.9 186 6.7 904 6.8
anticoagulants 26,716 39.0 19,323 36.9 1,064 38.3 6,329 47.7
statins 13,052 19.1 9,581 18.3 505 19.2 2,966 22.4
Other antidepressants 7,975 11.6 4,977 9.5 596 21.5 2,402 18.1
antipsychotics 4,992 7.3 2,899 5.5 319 11.5 1,774 13.4
Note: aBMi values from m =1 data.
Abbreviation: NSAIDs, non-steroidal anti-inflammatory drugs.
Table S6 incidences and hrs with 95% Cis of mortality within 30 days of hip fracture surgery according to selective serotonin 
reuptake inhibitor (ssri) use 2006–2016 (n=68,487) after imputation of BMi
Events Incidence (95% CI) Unadjusted HR (95% CI) Adjusteda HR (95% CI)
Current user 1,755 13.2 (12.7–12.8) 1.35 (1.28–1.43) 1.16 (1.10–1.22)
Former user 338 12.2 (11.0–12.5) 1.24 (1.11–1.38) 1.12 (1.00–1.24)
non-user 5,202 9.9 (9.7–10.2) 1.00 1.00
Notes: aadjusted for age, gender, marital status, BMi, operation year, myocardial infarction, congestive heart failure, peripheral vascular disease, dementia, chronic pulmonary 
disease, connective tissue disease, ulcer disease, liver disease, diabetes type 1 and 2, hemiplegia, moderate to severe renal disease, cancer, non-steroidal anti-inflammatory 
drugs, corticosteroids, anticoagulants, statins, non-ssri antidepressants, antipsychotics, and clustering by unit setting.
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
41
.3
5.
55
 o
n 
19
-S
ep
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2018:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1070
Bruun et al
Table S7 Baseline characteristics of hip fracture patients (n=68,487) according to preoperative selective serotonin reuptake inhibitor 
(SSRI) use 2006–2016 after changing the exposure definition
Variables All patients SSRIs
Non-users Former users Current users 
n % n % n % n %
Total 68,487 100 52,841 77.2 1,116 1.6 14,530 21.2
Median age (years) 83 83 82 84
Age (years)
65–74 13,271 19.4 10,620 20.1 230 20.6 2,421 16.6
75–84 26,086 38.1 19,910 37.7 487 43.6 5,689 39.2
≥85 29,130 42.5 22,311 42.2 399 35.8 6,420 44.2
Gender
Male 19,750 28.8 15,690 29.7 274 24.5 3,786 26.1
Female 48,737 71.2 37,151 70.3 842 75.5 10,744 73.9
Marital status
Married 20,300 29.6 16,247 30.7 320 28.7 3,733 25.7
Unmarried 48,187 70.4 36,594 69.3 796 71.3 10,797 74.3
Housing
Own accommodation 31,075 45.4 25,728 48.7 414 37.1 4,933 33.9
homeless 22 <0.1 17 <0.1 3 0.3 2 <0.1
residential institution 7,150 10.4 4,232 8.0 190 17.0 2,683 18.5
Unknown 30,285 44.2 22,864 43.3 509 45.6 6,912 47.6
Fracture type
Fracture of femoral neck 36,341 53.1 28.073 53.1 595 53.3 7.673 52.8
Per- and subtrochanteric fracture 32,146 46.9 24,768 46.9 521 46.7 6,857 47.2
Operation type
alloplastic surgery 46,859 68.4 36,122 68.4 761 68.2 9,976 68.7
Osteosynthesis 21,628 31.6 16,719 31.6 355 31.8 4,554 31.3
Operation delay (hours)
<24 41,671 60.8 32,090 60.7 700 62.7 8,881 61.1
24–48 12,517 18.3 9,715 18.4 196 17.6 2,606 17.9
>48 14,299 20.9 11,036 20.9 220 19.7 3,043 21.0
Operation year
2006–2010 32,131 46.9 24,061 45.5 539 48.3 7,531 51.8
2011–2016 36,356 53.1 28,780 54.5 577 51.7 6,999 48.2
BMI (kg/m2)
<18.5: underweight 5,988 8.8 4,623 8.7 104 9.3 1,261 8.7
≥18.5 <25: normal weight 31,582 46.1 24,630 46.6 492 44.1 6,460 44.5
≥25: overweight or obese 17,622 25.7 13,616 25.8 292 26.2 3,714 25.5
Unknown 13,295 19.4 9,972 18.9 228 20.4 3,095 21.3
Charlson Comorbidity Index
low (0) 27,283 39.8 22,655 42.9 339 30.4 4,289 29.5
Medium (1–2) 27,787 40.6 20,544 38.9 494 44.3 6,749 46.5
high (3+) 13,417 19.6 9,642 18.2 283 25.3 3,492 24.0
Comorbidity
Myocardial infarction 3,762 5.5 2,848 5.4 57 5.1 857 5.9
Congestive heart failure 6,289 9.2 4,677 8.9 125 11.2 1,487 10.2
Peripheral vascular disease 5,511 8.1 4,092 7.7 112 10.0 1,307 9.0
Cerebrovascular disease 12,678 18.5 8,549 16.2 278 24.9 3,851 26.5
Dementia 6,733 9.8 3,891 7.4 172 15.4 2,670 18.4
Chronic pulmonary disease 8,663 12.7 6,229 11.8 187 16.8 2,247 15.5
Connective tissue disease 3,243 4.7 2,495 4.7 60 5.4 688 4.7
Ulcer disease 3,855 5.6 2,693 5.1 81 7.3 1,081 7.4
liver disease 870 1.3 647 1.2 24 2.2 199 1.4
Diabetes type 1 and 2 6,689 9.8 5,041 9.5 131 11.7 1,517 10.4
hemiplegia 175 0.3 112 0.2 3 0.3 60 0.4
Moderate to severe renal disease 2,688 3.9 1,995 3.8 54 4.8 639 4.4
Cancer 10,957 16.0 8,440 16.0 175 15.7 2,342 16.1
(Continued)
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Table S8 incidences and hrs with 95% Cis of mortality within 30 days of hip fracture surgery according to selective serotonin 
reuptake inhibitor (ssri) use 2006–2016 (n=68,487) after changing the exposure definition
Events Incidence (95% CI) Unadjusted HR (95% CI) Adjusteda HR (95% CI)
Current user 1,907 13.1 (12.6–13.7) 1.34 (1.27–1.41) 1.16 (1.10–1.21)
Former user 137 12.3 (10.5–14.4) 1.25 (1.05–1.48) 1.12 (0.97–1.30)
non-user 5,251 9.9 (9.7–10.2) 1.00 1.00
Notes: aadjusted for age, gender, marital status, operation year, myocardial infarction, congestive heart failure, peripheral vascular disease, dementia, chronic pulmonary 
disease, connective tissue disease, ulcer disease, liver disease, diabetes type 1 and 2, hemiplegia, moderate to severe renal disease, cancer, non-steroidal anti-inflammatory 
drugs, corticosteroids, anticoagulants, statins, non-ssri antidepressants, antipsychotics, and clustering by unit setting.
Table S7 (Continued)
Variables All patients SSRIs
Non-users Former users Current users 
n % n % n % n %
Other medication
nsaiDs 7,681 11.2 5,926 11.2 128 11.5 1,627 11.2
Corticosteroids 4,158 6.1 3,100 5.9 86 7.7 972 6.7
anticoagulants 26,716 39.0 19,520 36.9 425 38.1 6,771 46.6
statins 13,052 19.1 9,698 18.4 182 16.3 3,172 21.8
Other antidepressants 7,975 11.6 4,905 9.3 372 33.3 2,698 18.6
antipsychotics 4,992 7.3 2,897 5.5 165 14.8 1,930 13.3
Abbreviation: NSAIDs, non-steroidal anti-inflammatory drugs.
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